Citadel Advisors’s Pharvaris PHVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.36M Buy
241,785
+73,155
+43% +$2.21M ﹤0.01% 3856
2026
Q1
$4.76M Buy
168,630
+33,561
+25% +$896K ﹤0.01% 4422
2025
Q4
$3.75M Buy
135,069
+5,331
+4% +$128K ﹤0.01% 4773
2025
Q3
$3.24M Buy
129,738
+100,517
+344% +$2.23M ﹤0.01% 5167
2025
Q2
$514K Buy
+29,221
New +$471K ﹤0.01% 8564
2024
Q3
Sell
-14,472
Closed -$272K 14978
2024
Q2
$272K Sell
14,472
-223,833
-94% -$4.55M ﹤0.01% 9331
2024
Q1
$5.51M Buy
238,305
+96,847
+68% +$2.57M ﹤0.01% 3801
2023
Q4
$3.97M Buy
+141,458
New +$2.86M ﹤0.01% 4141

Other funds holding PHVS

Citadel Advisors's PHVS Position: Q2 2026 in Review

Citadel Advisors increased its Pharvaris (PHVS) stake by 43% in Q2 2026, buying an estimated $2.21M and bringing the position to 241,785 shares worth $8.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3856.

Citadel Advisors first reported a position in PHVS in Q4 2023 and has held it in 8 quarters since. 125 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

  • Citadel Advisors held 241,785 shares of Pharvaris worth $8.36M as of Q2 2026.
  • Citadel Advisors bought 73,155 Pharvaris shares in Q2 2026, an estimated $2.21M.
  • Pharvaris made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3856 holding.
  • Citadel Advisors first reported a position in Pharvaris in Q4 2023 and has held it in 8 quarters since.
  • 125 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.